Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
Acta Pharmaceutica Sinica B, ISSN: 2211-3835, Vol: 13, Issue: 4, Page: 1467-1487
2023
- 13Citations
- 16Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes13
- 13
- CrossRef9
- Captures16
- Readers16
- 16
- Mentions1
- News Mentions1
- News1
Most Recent News
Researchers at University of Macau Have Published New Data on Cancer (Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives)
2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Data detailed on cancer have been presented. According to
Review Description
Described as a “don't eat me” signal, CD47 becomes a vital immune checkpoint in cancer. Its interaction with signal regulatory protein alpha (SIRP α ) prevents macrophage phagocytosis. In recent years, a growing body of evidences have unveiled that CD47-based combination therapy exhibits a superior anti-cancer effect. Latest clinical trials about CD47 have adopted the regimen of collaborating with other therapies or developing CD47-directed bispecific antibodies, indicating the combination strategy as a general trend of the future. In this review, clinical and preclinical cases about the current combination strategies targeting CD47 are collected, their underlying mechanisms of action are discussed, and ideas from future perspectives are shared.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2211383522005251; http://dx.doi.org/10.1016/j.apsb.2022.12.016; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85146272451&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37139405; https://linkinghub.elsevier.com/retrieve/pii/S2211383522005251; https://dx.doi.org/10.1016/j.apsb.2022.12.016; http://sciencechina.cn/gw.jsp?action=cited_outline.jsp&type=1&id=7454637&internal_id=7454637&from=elsevier
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know